



RESEARCH AND PRODUCT INNOVATION COMMITTEE CHARTER

PURPOSE

The purpose of the Research and Product Innovation Committee ("Committee") of the Board of Directors ("Board") of Myriad Genetics, Inc. ("Company") is to assist the Board in its oversight responsibilities by advising and consulting with the Company's management relating to product research, development and strategy.

ORGANIZATION

Charter Review. This charter shall be reviewed at least annually by the Committee and changes proposed by the Committee shall be submitted to the Board for approval.

Members. The Committee shall be composed of at least three members. Each member shall be a non-employee director of the Company. The entire Committee or any individual member of the Committee may be removed without cause by the affirmative vote of the majority of the Board. Any Committee member may resign effective upon giving oral or written notice to the Chair of the Board or the Secretary of the Company (unless the notice specifies a later time for the effectiveness of such resignation). The Nominating and Governance Committee may recommend, and the Board may elect, a successor to assume the available position on the Committee when the resignation becomes effective.

The members of the Committee shall be appointed by the Board on the recommendation of the Nominating and Governance Committee. The Chair of the Committee will be selected by the Board or the Chair of the Board. In the absence of such designation by the Board or the Chair of the Board, the members of the Committee may designate a Chair by majority vote of the full Committee members.

Meetings, Minutes, Reporting. The Committee shall meet not less than two (2) times per year at such times and places as it deems necessary to carry out its responsibilities. All Committee members are expected to attend each meeting, in-person or via tele- or video conference. The Chair of the Committee may call such meetings. The Chair of the Committee shall make an annual presentation to the Board regarding the Committee's activities and initiatives. The Committee shall keep minutes of the proceedings of the Committee. The Committee may appoint a Secretary to keep records of the Committee proceedings. The Secretary need not be a director and shall have no membership or voting rights by virtue of the position.

The Chair of the Committee shall determine the agenda for and the length of meetings and shall have unlimited access to management and information relating to the Committee's purposes. Meeting agendas will be prepared and, to the extent practicable, provided in advance to the members of the Committee, along with appropriate briefing materials. The Chair of the

Committee may establish such other rules as may from time to time be necessary and proper for the conduct of the business of the Committee.

Delegation. The Committee may, by resolution passed by a majority of the Committee members, designate one or more subcommittees, each subcommittee to consist of one or more members of the Committee. Any such subcommittee, to the extent provided in the resolutions of the Committee and to the extent not limited by applicable law, shall have and may exercise all the powers and authority of the Committee. Each subcommittee shall have such name as may be determined from time to time by resolution adopted by the Committee. Each subcommittee shall keep regular minutes of its meetings and report the same to the Committee or the Board when required.

Access to Officers and Employees. The Committee shall have the power to meet with any officer or employee of the Company and may invite any such persons to attend a Committee meeting.

Authority to Retain Advisors. The Committee shall have the authority, at the Company's expense and without needing to seek approval from the Board, to retain and terminate consultants, legal counsel, or other advisors, as the Committee deems advisable, including the sole authority to approve any such advisors' fees and retention terms.

Compensation. Committee members shall be compensated by the Company in the form of directors' fees, which may be paid in cash or equity of the Company. Committee members may, however, receive different compensation than that received for Board service by other Board members, in light of the nature of their responsibilities to the Company.

RESPONSIBILITIES

The Board delegates certain responsibilities to the Committee to assist the Board in fulfilling its oversight duties, including those duties and responsibilities set forth below. The duties and responsibilities are set forth below as a guide to the Committee, with the understanding that the Committee may alter or supplement them as appropriate under the circumstances, to the extent permitted by applicable law.

- I. The Committee shall interact with the Company's Chief Scientific Officer, Executive Vice President, Strategy and Innovation and other members of management and external advisors to review, evaluate, and provide insights and recommendations regarding the following:
 - a. the Company's product pipeline, clinical development and technical and commercial innovation;
 - b. maintaining alignment between strategic commercial objectives and the Company's product development;
 - c. evaluation and oversight of appropriate pipeline, technology, and product development investments;

- d. the prioritization of the innovation and technology needs of the Company;
 - e. the development and commercialization of the Company's existing and new product technologies in compliance with applicable regulatory requirements;
 - f. collaborating with the Company's scientific advisory board; and
 - g. early-stage merger and acquisition opportunities that would expand the Company's pipeline or product offerings.
- II. The Committee shall (1) advise management on all clinical trials and interactions with regulatory authorities, including the Food and Drug Administration; (2) evaluate existing and additional training for research and development personnel associated with the conduct of clinical test studies and the disclosure thereof; (3) advise the Board on clinical trials and any problems arising therefrom; and (4) oversee and/or advise management on the publication of clinical data in support of the Company's clinical research and product development efforts.
- III. The Committee shall also regularly consult with Company management and the Board concerning identified risks related to the development, acquisition, management, protection of intellectual property, and commercialization of the Company's product technologies.

Version: February 2025